Pharmacotherapy prescribing pattern and outcome for hospitalized patients with severe and critical COVID-19
, Pharmacotherapy prescribing pattern and outcome for hospitalized patients with severe and critical COVID-19
, , H., Current Issues in Pharmacy and Medical Sciences, doi:10.2478/cipms-2022-0020
Retrospective 346 hospitalized patients in Iraq, showing lower mortality with HCQ in unadjusted results. HCQ results are only provided within the 93% of patients treated with enoxaparin.
This study is excluded in the after exclusion results of meta
unadjusted results with no group details; confounding by time
possible, propensity to use HCQ changed significantly during the study period.
risk of death, 59.7% lower, RR 0.40, p = 0.002, treatment 9 of 72 (12.5%), control 68 of 219 (31.1%), NNT 5.4, enoxaparin+HCQ vs. enoxaparin.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Assad et al., 21 Oct 2022, retrospective, Iraq, peer-reviewed, 1 author, study period June 2020 - September 2020.
Abstract: DOI: 10.2478/cipms-2022-0020
Curr. Issues Pharm. Med. Sci., Vol. 35, No. 3, Pages 106-110
Current Issues in Pharmacy and Medical Sciences
Formerly ANNALES UNIVERSITATIS MARIAE CURIE-SKLODOWSKA, SECTIO DDD, PHARMACIA
journal homepage: http://www.curipms.umlub.pl/
Pharmacotherapy prescribing pattern and outcome
for hospitalized patients with severe and critical COVID-19
Department of Clinical Pharmacy, Faculty of Pharmacy, University of Kufa, Najaf, Iraq
Received 08 October 2021
Accepted 10 June 2022
There are many treatment modalities for COVID-19 – with varied outcome. Therefore,
authors designed this study to assess prescribing patterns and the clinical outcome
for hospitalized patients with severe and critical COVID-19 so as to determine the most
Authors conducted a retrospective observational study on 346 adult patients with either
severe or critical COVID-19, who were admitted to public hospitals in Al-Najaf city, Iraq
from June to September 2020. Patients' information, medications and outcomes were
collected from their medical records in the registered office of the hospital.
A total of 346 patients were enrolled, with a majority of patients being adults above 35 years
old and male (70.2%). Most patients (81%) received corticosteroid as dexamethasone, and
about 45% of all patients were given convalescent plasma therapy, while a few patients
were prescribed antiviral favipiravir (23%) and lopinavir/ritonavir (19%). As supportive
care medications, anticoagulant such as enoxaparin was administered to most of the
patients (93%) and more than half of all patients received the broad-spectrum antibiotic,
The majority of the patients recovered and were discharged alive (66%), however, the inhospital mortality rate was 26%. Interestingly, patients treated with enoxaparin alone
or in combination with hydroxychloroquine were associated with better outcome.
The prescribing pattern of COVID-19 specific medications and supportive care is aligned
with guideline recommendations and associated with a beneficial therapeutic outcome.
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.